Detalles de la búsqueda
1.
Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with CFTR Mutations Causing Pancreatic Insufficiency.
Int J Mol Sci
; 23(20)2022 Oct 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36293293
2.
Scoring Abdominal Symptoms in People with Cystic Fibrosis.
J Clin Med
; 13(6)2024 Mar 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38541878
3.
Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score.
Front Pharmacol
; 14: 1207356, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37205908
4.
Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years - The RECOVER study.
J Cyst Fibros
; 2023 Oct 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37806792
5.
Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.
Front Pharmacol
; 14: 1167407, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38026920
6.
The potential of volatile organic compound analysis for pathogen detection and disease monitoring in patients with cystic fibrosis.
Expert Rev Respir Med
; 16(7): 723-735, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35853615
7.
Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score.
Front Pharmacol
; 13: 877118, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35721187
8.
Antibody response against Pseudomonas aeruginosa and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients.
Pediatr Pulmonol
; 55(4): 959-967, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32022432
Resultados
1 -
8
de 8
1
Próxima >
>>